GLP-1 Drugs: Why Everyone Is Talking About Them

What GLP-1 Actually Is

GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally. It is made by specialized cells in your small intestine — called L cells — primarily in response to eating. When food enters your gut, L cells release GLP-1 into the bloodstream, where it does several important things simultaneously:

• Signals your pancreas to release insulin (but only when blood sugar is elevated)
• Tells your pancreas to reduce glucagon, a hormone that raises blood sugar
• Slows gastric emptying — meaning food moves more slowly through your stomach, keeping you feeling full longer
• Acts on appetite centers in the brain to reduce hunger

Natural GLP-1 has one critical limitation: it is broken down almost immediately by an enzyme called DPP-4. The half-life of natural GLP-1 is roughly 2 minutes. Your body makes it, it does its job, and it is gone. This rapid clearance is fine for normal metabolic regulation, but it makes natural GLP-1 useless as a drug — you would need continuous IV infusion to maintain therapeutic levels.

How Scientists Solved the Half-Life Problem

The story of GLP-1 drugs is fundamentally a story of peptide engineering. Researchers knew GLP-1 was a powerful metabolic signal, but they needed to make versions that lasted long enough to be practical as medications. The breakthrough came through molecular modifications:

Exenatide (Byetta), approved in 2005, was the first GLP-1 receptor agonist. It was based on exendin-4, a peptide found in the saliva of the Gila monster lizard, which naturally resists DPP-4 breakdown. It lasted long enough to be injected twice daily.

Liraglutide (Victoza/Saxenda) attached a fatty acid chain to the GLP-1 molecule, allowing it to bind to albumin in the blood and resist enzymatic breakdown. This extended the half-life to about 13 hours, enabling once-daily injection.

Semaglutide (Ozempic/Wegovy/Rybelsus) took this further with additional modifications that extended the half-life to approximately 7 days — enabling once-weekly injection. This was the drug that changed everything.

Tirzepatide (Mounjaro/Zepbound) went even further by targeting two receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), another gut hormone involved in metabolic regulation. This dual-agonist approach showed even greater efficacy in clinical trials.

The Weight Loss Mechanism

GLP-1 drugs were originally developed and approved for Type 2 diabetes — their ability to regulate blood sugar through insulin modulation was the primary therapeutic target. But during clinical trials, researchers noticed something striking: patients were losing significant amounts of weight.

The weight loss mechanism is multifaceted:

• Reduced appetite: GLP-1 receptor agonists act on hypothalamic neurons that regulate hunger and satiety. Patients consistently report that their desire to eat decreases significantly — not through willpower, but through a genuine reduction in hunger signals.
• Delayed gastric emptying: Food stays in the stomach longer, extending the feeling of fullness after meals.
• Reduced food reward: Emerging research suggests GLP-1 drugs may reduce the rewarding aspects of eating — particularly for high-calorie, high-fat foods. Some patients describe losing interest in foods they previously craved.
• Possible effects on other cravings: Early research (and significant anecdotal evidence) suggests GLP-1 drugs may reduce cravings for alcohol and other addictive substances, though this is still being studied.

The clinical trial data is striking. In the STEP trials, participants on semaglutide 2.4 mg weekly lost an average of about 15% of their body weight over 68 weeks. Tirzepatide trials (SURMOUNT) showed even higher numbers — up to 22.5% body weight reduction at the highest dose. These are results that rival surgical weight loss interventions.

Blood Sugar Regulation

While weight loss dominates headlines, the blood sugar effects of GLP-1 drugs are equally important and were the original reason for their development. GLP-1 receptor agonists improve glycemic control through several mechanisms:

• Glucose-dependent insulin secretion: They stimulate insulin release only when blood sugar is elevated — which means they carry a much lower risk of hypoglycemia (dangerously low blood sugar) compared to some older diabetes drugs.
• Glucagon suppression: They reduce the liver's output of glucose by suppressing glucagon.
• Beta cell preservation: Some evidence suggests GLP-1 drugs may help preserve and even restore the insulin-producing beta cells of the pancreas, potentially modifying the disease course of Type 2 diabetes rather than just managing symptoms.

Why Demand Exploded

Several factors converged to create the GLP-1 phenomenon:

Efficacy that was impossible to ignore. Previous weight loss drugs typically produced modest results — 5% to 10% body weight loss was considered a success. GLP-1 drugs shattered those benchmarks.

Celebrity and social media attention. High-profile users brought GLP-1 drugs into mainstream awareness almost overnight, creating enormous consumer demand that pharmaceutical supply chains were not prepared for.

The obesity paradigm shift. GLP-1 drugs arrived at a cultural moment when the medical establishment was increasingly recognizing obesity as a chronic metabolic disease rather than a failure of willpower. These drugs provided a pharmacological tool that validated that framing.

Compounding pharmacy access. When FDA-approved GLP-1 drugs experienced severe shortages, compounding pharmacies began producing versions of semaglutide and tirzepatide, making the drugs more accessible and often more affordable (though this access has its own regulatory complexities, covered in a later article).

Important Caveats

GLP-1 drugs are not without limitations and risks. Common side effects include nausea, vomiting, diarrhea, and constipation — particularly during dose escalation. More serious but rarer concerns include pancreatitis, gallbladder issues, and potential thyroid effects (a boxed warning based on animal data). There are also important questions about muscle mass loss during rapid weight reduction, and what happens when patients discontinue the medication (most studies show significant weight regain).

These are powerful drugs with strong evidence behind them — but they are not magic, and they are not for everyone. A thorough understanding of both their benefits and limitations is essential.

The next article addresses a question that comes up immediately when people start exploring peptide therapy: what exactly is a compounding pharmacy, and how do you know if one is legitimate?